Log in
NASDAQ:MBIO

Mustang Bio Stock Forecast, Price & News

$3.88
+0.28 (+7.78 %)
(As of 09/19/2020 12:27 AM ET)
Add
Compare
Today's Range
$3.42
Now: $3.88
$4.03
50-Day Range
$3.03
MA: $3.30
$3.79
52-Week Range
$1.78
Now: $3.88
$4.85
Volume8.70 million shs
Average Volume736,782 shs
Market Capitalization$219.51 million
P/E RatioN/A
Dividend YieldN/A
Beta1.62
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develop MB-107, a gene therapy program, potential curative treatment for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. Its ex vivo lentiviral gene therapy is in two Phase I/II clinical trials. The company also develops CD123, a heterodimeric interleukin-3-receptor for acute myeloid leukemia; CD20 for immunotherapy of B-cell lymphomas; CS1, an NK cell receptor regulating immune functions; IL13Ra2 CAR T cell program for glioblastoma; HER2 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; and PSCA CAR T for prostate and pancreatic cancers. It has a license agreement with Harvard University for the treatment of cancer; Nationwide Children's Hospital for the development of an oncolytic virus for treating GBM; and Beth Israel Deaconess Medical Center to perform research relating to gene editing. The company was incorporated in 2015 and is headquartered in New York, New York. Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.
Read More
Mustang Bio logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.31 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MBIO
CUSIPN/A
Phone781-652-4500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.25 per share

Profitability

Net Income$-46,390,000.00

Miscellaneous

Employees38
Market Cap$219.51 million
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$3.88
+0.28 (+7.78 %)
(As of 09/19/2020 12:27 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for MBIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Mustang Bio (NASDAQ:MBIO) Frequently Asked Questions

How has Mustang Bio's stock been impacted by Coronavirus?

Mustang Bio's stock was trading at $2.35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MBIO shares have increased by 65.1% and is now trading at $3.88.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Mustang Bio?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mustang Bio in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Mustang Bio
.

When is Mustang Bio's next earnings date?

Mustang Bio is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Mustang Bio
.

How were Mustang Bio's earnings last quarter?

Mustang Bio Inc (NASDAQ:MBIO) posted its quarterly earnings data on Monday, August, 10th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.27) by $0.05.
View Mustang Bio's earnings history
.

What price target have analysts set for MBIO?

3 brokerages have issued 12-month price objectives for Mustang Bio's stock. Their forecasts range from $7.00 to $13.00. On average, they expect Mustang Bio's stock price to reach $9.00 in the next year. This suggests a possible upside of 132.0% from the stock's current price.
View analysts' price targets for Mustang Bio
.

Are investors shorting Mustang Bio?

Mustang Bio saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 1,080,000 shares, an increase of 11.8% from the August 15th total of 966,300 shares. Based on an average daily volume of 1,170,000 shares, the short-interest ratio is currently 0.9 days. Approximately 3.4% of the company's stock are sold short.
View Mustang Bio's Short Interest
.

Who are some of Mustang Bio's key competitors?

What other stocks do shareholders of Mustang Bio own?

Who are Mustang Bio's key executives?

Mustang Bio's management team includes the following people:
  • Mr. Michael S. Weiss, Exec. Chairman (Age 53)
  • Dr. Manuel Litchman, Pres, CEO & Director (Age 65)
  • Mr. David Jay Horin CPA, Interim Chief Financial Officer (Age 51)
  • Mr. Brian K. Achenbach, VP of Fin. & Corp. Controller (Age 54)
  • Dr. Knut Niss, Chief Technology Officer

What is Mustang Bio's stock symbol?

Mustang Bio trades on the NASDAQ under the ticker symbol "MBIO."

Who are Mustang Bio's major shareholders?

Mustang Bio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Schonfeld Strategic Advisors LLC (0.69%), Alyeska Investment Group L.P. (0.87%), FNY Investment Advisers LLC (0.58%), Sabby Management LLC (0.55%), Telemetry Investments L.L.C. (0.53%) and Bridgeway Capital Management Inc. (0.34%). Company insiders that own Mustang Bio stock include Lindsay A Md Rosenwald and Manuel Md Litchman.
View institutional ownership trends for Mustang Bio
.

Which major investors are selling Mustang Bio stock?

MBIO stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Bank of New York Mellon Corp, and Algert Global LLC.
View insider buying and selling activity for Mustang Bio
.

Which major investors are buying Mustang Bio stock?

MBIO stock was acquired by a variety of institutional investors in the last quarter, including Schonfeld Strategic Advisors LLC, Alyeska Investment Group L.P., Sabby Management LLC, Telemetry Investments L.L.C., Jacobs Levy Equity Management Inc., Goldman Sachs Group Inc., Sigma Planning Corp, and FNY Investment Advisers LLC. Company insiders that have bought Mustang Bio stock in the last two years include Lindsay A Md Rosenwald, and Manuel Md Litchman.
View insider buying and selling activity for Mustang Bio
.

How do I buy shares of Mustang Bio?

Shares of MBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mustang Bio's stock price today?

One share of MBIO stock can currently be purchased for approximately $3.88.

How big of a company is Mustang Bio?

Mustang Bio has a market capitalization of $219.51 million. The company earns $-46,390,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. Mustang Bio employs 38 workers across the globe.

What is Mustang Bio's official website?

The official website for Mustang Bio is www.mustangbio.com.

How can I contact Mustang Bio?

Mustang Bio's mailing address is 377 PLANTATION STREET, WORCESTER MA, 01605. The company can be reached via phone at 781-652-4500 or via email at [email protected]

This page was last updated on 9/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.